Pectoralis major radiation recall

Emma Hack, MBBS, Thanuja Thachil, MBBS, FRANZCR, & Narayan Karanth, MBBS, FRACP

Department of Medicine, Royal Darwin Hospital, Tiwi, Northern Territory, Australia

Keywords
adverse events, chest, clinical site, discipline, general, medical imaging, radiation oncology

Abstract
Radiation recall is an uncommon phenomenon describing an acute localised inflammatory toxicity affecting tissue previously exposed to radiotherapy. It is precipitated by administration of certain medications, including chemotherapy. We describe a case involving a 50-year-old Aboriginal male smoker from a remote community in Northern Australia who underwent treatment for stage IV non-small cell lung cancer with localised radiotherapy to the primary right upper lung lobe tumour. This was followed by a course of gemcitabine, which was ceased prematurely after four cycles when he presented with radiation recall to his right pectoralis major. Our case description is complemented with a brief review of current literature regarding our case and gemcitabine-related radiation recall. This was in the context of concurrent musculoskeletal strain, an as-yet unreported association with radiation recall. His condition settled with steroid administration and discontinuation of gemcitabine.

Case Report
A 50-year-old Aboriginal male smoker from a remote community in Northern Australia presented with a 6-month history of weight loss and anaemia. Subsequent investigation revealed a 62 × 111 × 72 mm stage IV right upper lobe non-small cell lung adenocarcinoma (epidermal growth factor receptor, anaplastic lymphoma kinase, kirsten rat sarcoma viral oncogene mutation wild-type) with supraclavicular nodal and splenic metastases (T3N3M1b). Other medical history included latent tuberculosis for which he was taking isoniazid 250 mg daily and pyridoxine 25 mg daily, chronic kidney disease, emphysema managed with salbutamol inhaler as needed and hypertension treated with ramipril 1.25 mg daily.

He relocated to a tertiary medical facility to undergo palliative chemoradiotherapy. He completed 2 weeks of radiotherapy with four beams at 20–30 Gy in 10 fractions with 3D conformal technique to the primary tumour, with planning target volume covered by 95% of the isodose line. The ipsilateral breast including pectoralis major received dose ranging from 15 to 30 Gy (Fig. 1). One month later, he commenced three weekly cycles of palliative chemotherapy with gemcitabine and carboplatin. One week after his fourth cycle he presented to the local emergency department with increasing pain and swelling to the right breast (Fig. 2). He had participated in heavy lifting 2 weeks prior and recalled bilateral achiness to his arms following the activity. He had not commenced any other medications and did not drink alcohol.

The patient was haemodynamically stable and afebrile. Marked right breast asymmetry was noted with a firm, immobile, tender, warm right breast swelling. There were no overlying skin changes. Laboratory results revealed an acute kidney injury with creatinine level 123 µmol/L (60–110) and egfr 52 mL/min/1.72m² (baseline 65–70) along with an elevated creatine kinase at 374 IU/L (40–200). White cell count was normal, though C-reactive peptide was elevated at 94 mg/L (5). Haemoglobin was 93 g/L unchanged from previous (130–180). Anti-signal recognition antibodies were positive. Transcription intermediary factor 1-gamma antibodies were negative. Incision and exploration of the swelling showed diffuse muscular hypertrophy with no evidence of abscess or haematoma. Subsequent biopsy confirmed acute non-specific myositis (Fig. 3). Microscopy and culture were negative. The patient gave permission for the case report to be published.

Discussion
Radiation recall is an acute localised inflammatory toxicity affecting tissue previously exposed to...
Figure 1. Radiotherapy planning. Pectoralis major received 15–30 Gy. Gross tumour volume = red colour wash, clinical tumour volume = orange colour wash, planned tumour volume = blue colour wash.

Figure 2. Right pectoralis major swelling.
radiotherapy. It is always precipitated by administration of specific medications. Since the phenomenon was first described in literature in 1959, it has been associated with a number of agents including chemotherapy, targeted therapies (such as mammalian target of rapamycin or epidermal growth factor receptor inhibitors), antibiotics, anti-oestrogen therapy and statins. In general, manifestation of radiation recall varies, and may range from mild superficial cutaneous reactions such as dermatitis, to less-common deeper reactions including myositis. Pathogenesis is unclear though it is hypothesised that radiation recall represents a variant of idiosyncratic hypersensitivity as accumulative previous cell damage from radiotherapy sensitises tissue to the cytotoxic effects of certain drugs.

Chemotherapeutic agents are particularly linked to the phenomenon which can occur at any time varying from days to years after completing radiotherapy. Gemcitabine is an antimetabolite chemotherapeutic agent frequently used as first line treatment in non-small cell lung cancer. Gemcitabine-related radiation recall has been implicated in a number of case reports, manifesting as dermatitis, myositis, dermatomyositis, pericardial effusion, pulmonary fibrosis, vaginal necrosis, rectal haemorrhage, gastritis, esophagitis, and compartment syndrome. It has also been suggested that as compared to other agents, gemcitabine-associated radiation recall may be more frequently associated with deeper-organ and tissue reactions (such as myositis) as opposed to superficial reactions such as dermatitis. Furthermore, there are reports of a dose-responsive relationship between amount of radiotherapy received and risk of developing radiation recall.

There are few case reports specifically documenting gemcitabine-associated radiation recall of pectoralis major – though we identified two cases in patients receiving treatment for non-small cell lung cancer and one in a patient with non-hodgkins lymphoma. Musculoskeletal injury as a precipitant or contributing factor to radiation recall has not been reported in the literature to our knowledge.

There are no widely accepted guidelines on managing radiation recall. The consensus in available literature indicates discontinuation of the chemotherapeutic agent coupled with steroid or anti-inflammatory treatment seems to resolve the condition. Many clinicians recommend permanent discontinuation of the causative medication while others suggest re-challenging the patient with the offending chemotherapeutic agent with some reports of success.

Our patient commenced a weaning course of oral dexamethasone and the chemotherapy regime was discontinued with clinical improvement over several weeks. Future plans for administration of chemotherapeutic agents for this patient were abandoned. He later commenced a programmed cell death protein 1 inhibitor in the form of nivolumab as second-line therapy.

Our patient experienced localised pectoralis major radiation recall, possibly unique as a result of gemcitabine potentiated by concurrent musculoskeletal strain in the context of radiotherapy given 4 months earlier. Radiation recall has important clinical implications for patients with cancer and may affect the clinician’s ability to administer important treatment.

Conflict of Interest

The authors declare no conflict of interest.

References

1. D’Angio G, Farber S, Maddock CL. Potentiation of x-ray effects of actinomycin D. Radiology 1959; 73: 175–7.
2. Burris HA, Hurtig J. Radiation recall with anticancer agents. Oncologist 2010; 15: 1227–37.
3. Kellie S, Plowman P, Malpas J. Radiation recall and radiosensitisation with alkylating agents. Lancet 1987; 1: 1149–50.
4. Levy A, Hollebecque A, Bourgier C, et al. Targeted-therapy induced radiation recall. Eur J Cancer 2013; 49: 1662–8.
5. Vujovic O. Radiation recall dermatitis with azithromycin. Curr Oncol 2010; 17: 119–21.
6. Kang SK. Images in clinical medicine. Radiation recall reaction after antimicrobial therapy. N Engl J Med 2006; 354: 622.
7. Friedlander P, Bansal R, Schwartz L, Wagman R, Posner J, Kemeny N. Gemcitabine-related radiation recall preferentially involves internal tissues and organs. Cancer 2004; 100: 1793–9.
8. Singer EA, Warren RD, Pennanen MF, Collins BF, Hayes DF. Tamoxifen-induced radiation recall dermatitis. Breast J 2002; 10: 170–1.
9. Jeter MD, Janne PA, Brooks S, et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys 2002; 53: 394–400.
10. Abadir R, Liebmann J. Radiation reaction recall following simvastatin therapy: A new observation. Clin Oncol (R Coll Radiol) 1995; 7: 325–302.
11. Burnstein HJ. Radiation recall following gemcitabine. Lung Cancer 2001; 33: 299–302.
12. Maeng C, Park J, Lee S, et al. Radiation recall phenomenon presenting as myositis triggered by carboplatin plus paclitaxel and related literature review. J Cancer Res Ther 2014; 10: 1093–7.
13. Fakih MG. Gemcitabine-induced rectus abdominus radiation recall. J Pancreas 2014; 10: 784–5.
14. Biswas J, Dutta S, Sharma S, Choudhury KB. Gemcitabine-induced radiation recall phenomenon in a post-operative radiotherapy case of peri-ampullary carcinoma during adjuvant chemotherapy. J Cancer Res Ther 2012; 8: 439–41.
15. Skarin A. Side effects of chemotherapy: Radiation recall dermatitis from gemcitabine. J Clin Oncol 2000; 18: 693–8.
16. Spielmann L, Messer L, Moreau P, Etienne E, Meyer C, Sibilia J, et al. Gemcitabine-induced myopathy. Semin Arthritis Rheum 2014; 43: 784–91.
17. Ardavanis AS, Ioannidis GN, Rigatos GA. Acute myopathy in a patient with lung adenocarcinoma treated with gemcitabine and docetaxel. Anticancer Res 2005; 25(1B): 523.
18. Delavan JA, Chino JP, Vinson EN. Gemcitabine-induced radiation recall myositis. Skeletal Radiol 2015; 44: 451–5.
19. Patel S, Paulino A, Johnston D, Wiederhold L, Castillo R, Venktramani R. Gemcitabine-induced radiation recall myositis in a patient with relapsed nasopharyngeal carcinoma. Pract Radiat Oncol 2017; 7: e19–22.
20. Graf SW, Limaye VS, Cleland LG. Gemcitabine-induced radiation recall myositis in a patient with dermatomyositis. Int J Rheum Dis 2014; 17: 696–7.
21. Vogl DT, Glatstein E, Carver JR, et al. Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation. Leuk Lymphoma 2005; 46: 1313–20.
22. Faiz S, Diwakar D, Balachandran L, Shannon V. Pulmonary radiation recall induced by gemcitabine. Am J Respir Circ Care Med 2016; 194: 909–10.
23. Gabel C, Eisel PJ, Tornos C, Burke TW. Radiation recall reaction to idarubicin resulting in vaginal necrosis. Gynaecol Oncol 1995; 57: 266–9.
24. Nishimoto K, Akise Y, Miyazawa M, Kutsuki S, Hashimoto S, Uchida A. A case of severe rectal haemorrhage possibly caused by radiation recall after administration of gemcitabine. Keio J Med 2016; 65: 16–20.
25. Choi SJ, Kim HJ, Kim JS, Bak Y, Kim JS. Radiation recall gastritis secondary to combination of gemcitabine and erlotinib in pancreatic cancer and response to PPI – a case report. BMC Cancer 2016; 16: 588.
26. Eckardt MA, Bean A, Selch MT, Federman N. A child with gemcitabine-induced severe radiation recall myositis resulting in a compartment syndrome. J Pediatr Hematol Oncol 2013; 35: 156–61.
27. Mallik S, Gupta S, Munshi A. Memoirs of differential radiation doses: Gemcitabine induced radiation recall. Acta Oncol 2010; 49: 261–2.
28. Alco G, Igdem S, Dincer M, et al. Gemcitabine induced radiation recall myositis: Report of two cases. Int J Hematol Oncol 2009; 4: 249–53.
29. Horan G, Smith S, Podd T. Gemcitabine-induced radiation necrosis of the pectoralis major muscle. Clin Oncol 2006; 18: 85–91.
30. O’Regan K, Nishino M, Armand P, Kelly P, Hwang D, Di Salvo D. Sonographic features of pectoralis major necrosis secondary to gemcitabine induced radiation recall. J Ultrasound Med 2010; 29: 1499–502.
31. Lock M, Sinclair K, Welch S, Salim M. Radiation recall dermatitis due to gemcitabine does not suggest the need to discontinue chemotherapy. Oncol Lett 2011; 2: 85–90.